By: Andrew Dunn
Faro AI raises $37M Series B led by Merck Global Health Innovation Fund and S32 to cut clinical trial timelines by 50% in five years using AI.
Andrew Dunn is a senior biopharma correspondent at Endpoints News. He focuses on uncovering and explaining the future of the biotech and pharmaceutical industries, with particular interests in AI's role in biotech, cell and gene therapy, and the intersection of money and medicine. His work has been featured in prominent outlets including Yahoo News UK, Business Insider, and Forbes.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Charlotte, United States (Local)
Not enough data
Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.
Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.
As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .